Big Health, a leading developer of digital treatments for the most pervasive mental health conditions, today announced a new round of strategic funding of $23.7 million to accelerate access to its FDA-cleared, reimbursable solutions (SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder (GAD))..

大型健康公司是开发最普遍心理健康状况数字治疗方案的领先者，今天宣布了一轮2370万美元的新战略融资，以加速获取其经FDA批准、可报销的解决方案（针对失眠症的SleepioRx和针对广泛性焦虑症(GAD)的DaylightRx）。

Big Health's mission is to help millions improve their mental health by providing safe and effective digital treatments for the most common mental health conditions, including insomnia and anxiety. Designed by leading clinical experts, Big Health's digital mental health treatments expand access to gold'standard care, including behavioral medicine, and are backed by industry'leading research and randomized controlled trials.

Big Health的使命是通过为最常见的心理健康问题（包括失眠和焦虑）提供安全有效的数字治疗方案，帮助数百万人改善他们的心理健康。Big Health的数字心理健康治疗方案由领先的临床专家设计，扩展了获取黄金标准护理（包括行为医学）的途径，并得到了行业领先的研究和随机对照试验的支持。

By making treatments available both directly to patients and through providers, and by simplifying adoption for providers, payers, and employers, Big Health is increasing access to affordable evidence-based care..

通过直接向患者以及通过医疗服务提供者提供治疗，并简化提供者、支付方和雇主的采纳流程，Big Health 正在增加人们获得负担得起的循证护理的机会。